Reinforcing Effects of Cathinone NPS in the Intravenous Drug Self-Administration Paradigm

Abstract

Since the mid- to late 2000s, there has been a dramatic rise in the use and abuse of synthetic derivatives of cathinone, a stimulant alkaloid found in the African shrub Catha edulis. Cathinone novel psychoactive substances (NPS), also referred to as synthetic cathinones or “bath salt”-type drugs, have gained popularity among drug users due to their potency, low cost, ease of procurement, and diverse array of evolving chemical structures. While the ability of cathinone NPS to produce psychotomimetic effects, multiple organ system toxicity, and death in humans is well documented, there has been limited scientific investigation into the reinforcing effects and abuse liability of these drugs. In this chapter, we will summarize the existing literature on the reinforcing effects of cathinone NPS in rodents using the intravenous self-administration (IVSA) paradigm. We will also compare the ability of cathinone NPS to serve as reinforcers to that of classical psychostimulants such as cocaine, methamphetamine, and methylenedioxymethamphetamine (MDMA). The chapter will conclude with a summary and indications for future avenues of research on cathinone NPS.

Keywords

Cathinone Reinforcement Intravenous self-administration Animal model Operant conditioning 

References

  1. 1.
    Association of Poison Control Centers (2013) Bath salts data. 30 April 2013Google Scholar
  2. 2.
    Baumeister D, Tojo LM, Tracy DK (2015) Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol 5:97–132CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Karch SB (2015) Cathinone neurotoxicity (“the 3Ms”). Curr Neuropharmacol 13:21–25CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Underwood E (2015) A new drug war. Science 347:469–473CrossRefPubMedGoogle Scholar
  5. 5.
    Weaver MF, Hopper JA, Gunderson EW (2015) Designer drugs 2015: assessment and management. Addict Sci Clin Pract 10:8CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zawilska JB (2015) “Legal highs” - an emerging epidemic of novel psychoactive substances. Int Rev Neurobiol 120:273–300CrossRefPubMedGoogle Scholar
  7. 7.
    Banks ML, Worst TJ, Rusyniak DE, Sprague JE (2014) Synthetic cathinones (“bath salts”). J Emerg Med 46:632–642CrossRefPubMedGoogle Scholar
  8. 8.
    Froberg BA, Levine M, Beuhler MC, Judge BS, Moore PW, Engebretsen KM, McKeown NJ, Rosenbaum CD, Young AC, Rusyniak DE (2015) Acute methylenedioxypyrovalerone toxicity. J Med Toxicol 11:185–194CrossRefPubMedGoogle Scholar
  9. 9.
    Hall C, Heyd C, Butler C, Yarema M (2014) “Bath salts” intoxication: a new recreational drug that presents with a familiar toxidrome. CJEM 16:171–176CrossRefPubMedGoogle Scholar
  10. 10.
    Karila L, Megarbane B, Cottencin O, Lejoyeux M (2015) Synthetic cathinones: a new public health problem. Curr Neuropharmacol 13:12–20CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Batisse A, Fortias M, Bourgogne E, Gregoire M, Sec I, Djezzar S (2014) Case series of 21 synthetic cathinones abuse. J Clin Psychopharmacol 34:411–413CrossRefPubMedGoogle Scholar
  12. 12.
    Baumann MH (2014) Awash in a sea of ‘bath salts’: implications for biomedical research and public health. Addiction 109:1577–1579CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Capriola M (2013) Synthetic cathinone abuse. Clin Pharmacol Adv Appl 5:109–115Google Scholar
  14. 14.
    Fass JA, Fass AD, Garcia AS (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 46:436–441CrossRefPubMedGoogle Scholar
  15. 15.
    Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D (2014) Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil 5:37–52PubMedPubMedCentralGoogle Scholar
  16. 16.
    Sadeg N, Darie A, Vilamot B, Passamar M, Frances B, Belhadj-Tahar H (2014) Case report of cathinone-like designer drug intoxication psychosis and addiction with serum identification. Addict Disord Treat 13:38–43CrossRefGoogle Scholar
  17. 17.
    Winder GS, Stern N, Hosanagar A (2013) Are “bath salts” the next generation of stimulant abuse? J Subst Abuse Treat 44:42–45CrossRefPubMedGoogle Scholar
  18. 18.
    Watterson LR, Olive MF (2014) Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv Neurosci 2014:209875CrossRefGoogle Scholar
  19. 19.
    Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552–562CrossRefPubMedGoogle Scholar
  20. 20.
    Cameron K, Kolanos R, Verkariya R, De Felice L, Glennon RA (2013) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl) 227:493–499CrossRefGoogle Scholar
  21. 21.
    Cameron KN, Kolanos R, Solis E, Glennon RA, De Felice LJ (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750–1757CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Coppola M, Mondola R (2012) 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12–15CrossRefPubMedGoogle Scholar
  23. 23.
    De Felice LJ, Glennon RA, Negus SS (2014) Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. Life Sci 97:20–26CrossRefPubMedGoogle Scholar
  24. 24.
    Glennon RA (2014) Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv Pharmacol 69:581–620CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kolanos R, Partilla JS, Baumann MH, Hutsell BA, Banks ML, Negus SS, Glennon RA (2015) Stereoselective actions of methylenedioxypyrovalerone (MDPV) to inhibit dopamine and norepinephrine transporters and facilitate intracranial self-stimulation in rats. ACS Chem Neurosci 6:771–777CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kolanos R, Solis EJ, Sakloth F, De Felice LJ, Glennon RA (2013) “Deconstruction” of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem Neurosci 4:1524–1529CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener M, Liechti M (2013) Pharmacological characterization of designer cathinones in vitro. J Comp Neurol 168:458–470Google Scholar
  28. 28.
    Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203CrossRefPubMedGoogle Scholar
  29. 29.
    Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803–1815CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lopez-Arnau R, Martinez-Clemente J, Carbo M, Pubill D, Escubedo E, Camarasa J (2013) An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts”. Prog Neuropsychopharmacol Biol Psychiatry 45:64–72CrossRefPubMedGoogle Scholar
  31. 31.
    Cozzi NV, Sievert MK, Shulgin AT, Jacob P III, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by Beta-keto amphetamines. Eur J Pharmacol 381:63–69CrossRefPubMedGoogle Scholar
  32. 32.
    Pifl C, Reither H, Hornykiewicz O (2015) The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter. Eur J Pharmacol 755:119–126CrossRefPubMedGoogle Scholar
  33. 33.
    Gosnell BA, Yracheta JM, Bell SM, Lane KE (1996) Intravenous self-administration of cathinone by rats. Behav Pharmacol 7:526–531PubMedGoogle Scholar
  34. 34.
    Kaminski BJ, Griffiths RR (1994) Intravenous self-injection of methcathinone in the baboon. Pharmacol Biochem Behav 47:981–983CrossRefPubMedGoogle Scholar
  35. 35.
    Woolverton WL, Johanson CE (1984) Preference in rhesus monkeys given a choice between cocaine and d, l-cathinone. J Exp Anal Behav 41:35–43CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Watterson LR, Watterson E, Olive MF (2013) Abuse liability of novel ‘legal high’ designer stimulants: evidence from animal models. Behav Pharmacol 24:341–355CrossRefPubMedGoogle Scholar
  37. 37.
    Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530–536CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Aarde SM, Angrish D, Barlow DJ, Wright MJJ, Vandewater SA, Creehan KM, Houseknecht KL, Dickerson TJ, Taffe MA (2013) Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol 18:768–799CrossRefGoogle Scholar
  39. 39.
    Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L (2006) Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 186:48–53CrossRefGoogle Scholar
  40. 40.
    Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM, Wyatt N, Callaghan PD, Bowen MT, Cornish JL, McGregor IS (2013) High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine. J Psychopharmacol 27:823–836CrossRefPubMedGoogle Scholar
  41. 41.
    Creehan KM, Vandewater SA, Taffe MA (2015) Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92:90–97CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Vandewater SA, Creehan KM, Taffe MA (2015) Intravenous self-administration of entactogen-class stimulants in male rats. Neuropharmacology 99:538–545CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71:130–140CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Aarde SM, Huang PK, Dickerson TJ, Taffe MA (2015) Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats. Psychopharmacology (Berl) 232:1867–1877CrossRefGoogle Scholar
  45. 45.
    Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19:165–174CrossRefPubMedGoogle Scholar
  46. 46.
    Schindler CW, Thorndike EB, Goldberg SR, Lehner KR, Cozzi NV, Brandt SD, Baumann MH (2016) Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology (Berl) 233:1981–1990CrossRefGoogle Scholar
  47. 47.
    Watterson LR, Hood LE, Sewalia K, Johnson CT, Wegner S, Grabenauer M, Thomas BF, Marusich JA, Olive MF (2012) The reinforcing effects of the methylone, a synthetic cathinone commonly found in “bath salts”. J Addict Res Ther S9:002Google Scholar
  48. 48.
    Watterson LR, Burrows BT, Hernandez RD, Moore KN, Grabenauer M, Marusich JA, Olive MF (2014) Effects of α-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation “bath salts,” on intracranial self-stimulation thresholds in rats. Int J Neuropsychopharmacol 18:1–9Google Scholar
  49. 49.
    Aarde SM, Creehan KM, Vandewater SA, Dickerson TJ, Taffe MA (2015) In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology (Berl) 232:3045–3055CrossRefPubMedCentralGoogle Scholar
  50. 50.
    Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Roberts DCS, Phelan R, Hodges LM, Hodges MM, Bennett B, Childers S, Davies H (1999) Self-administration of cocaine analogs by rats. Psychopharmacology (Berl) 144:389–397CrossRefGoogle Scholar
  52. 52.
    Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848–854CrossRefPubMedGoogle Scholar
  53. 53.
    Wee S, Carroll FI, Woolverton WL (2006) A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology 31:351–362CrossRefPubMedGoogle Scholar
  54. 54.
    Gass JT, Olive MF (2008) Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 75:218–265CrossRefPubMedGoogle Scholar
  55. 55.
    Liberles SD (2015) Trace amine-associated receptors: ligands, neural circuits, and behaviors. Curr Opin Neurobiol 34:1–7CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of PsychologyArizona State UniversityTempeUSA

Personalised recommendations